Clinical Trial Update: A Trial of Androgen Deprivation, Docetaxel, and Enzalutamide for Metastatic Prostate Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update evaluating androgen deprivation combined with docetaxel and enzalutamide for metastatic prostate cancer; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Adenocarcinoma
• Prostate Cancer

Drugs mentioned

• Docetaxel (Taxotere) (docetaxel)
• Enzalutamide (Xtandi) (enzalutamide)

Snippet

Sponsor: Wake Forest University Health Sciences | Conditions: Prostate Cancer, Prostate Adenocarcinoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2023-09-22